一氧化碳弥散量与超声心动图参数在EUSTAR系统性硬化症队列中识别轻度肺动脉高压
研究基于EUSTAR数据库,纳入有TAPSE、sPAP和mPAP数据的系统性硬化症患者,比较mPAP 21-24 mmHg组与mPAP≤20 mmHg组。TAPSE/sPAP在mPAP 21-24 mmHg组低于非PH组(0.58 vs 0.69 mm/mmHg,P<.01),其他参数无差异。一氧化碳弥散量<预计值80%敏感性88.9%、NPV 80%,但特异性18.2%、PPV 30.8%;TAPSE/sPAP<0.55 mm/mmHg特异性78.9%、PPV 50%、准确率68.1%,敏感性45.1%、NPV 75.4%。作者认为TAPSE/sPAP<0.55 mm/mmHg可作为减少不必要右心导管的附加参数。
要点
- 在系统性硬化症患者中,一氧化碳弥散量<预计值80%识别右心导管mPAP 21-24 mmHg的敏感性88.9%、NPV 80%,特异性仅18.2%、PPV 30.8%。
- TAPSE/sPAP<0.55 mm/mmHg识别mPAP 21-24 mmHg的特异性78.9%、PPV 50%、准确率68.1%,敏感性45.1%、NPV 75.4%。
- mPAP 21-24 mmHg组TAPSE/sPAP低于非PH组(0.58 vs 0.69 mm/mmHg,P<.01),其他参数两组无差异。
- 2022年欧洲心脏病学会/欧洲呼吸学会指南定义肺动脉高压为右心导管静息mPAP>20 mmHg。
- 作者认为TAPSE/sPAP<0.55 mm/mmHg可作为附加参数以减少不必要的右心导管。
适用人群与场景
- 来自欧洲硬皮病试验与研究(EUSTAR)数据库、有TAPSE、sPAP和mPAP数据的系统性硬化症患者。
- 分析纳入mPAP 21-24 mmHg患者与mPAP≤20 mmHg患者。
诊断标准与关键阈值
- 2022年欧洲心脏病学会/欧洲呼吸学会指南定义肺动脉高压为右心导管静息mPAP>20 mmHg。
- 既往mPAP 21-24 mmHg被归为临床意义不明确的「灰区」。
- 一氧化碳弥散量<预计值80%为筛查阈值。
- TAPSE/sPAP<0.55 mm/mmHg为筛查阈值。
研究设计与关键结果
- 研究基于EUSTAR数据库,纳入有TAPSE、sPAP和mPAP数据的系统性硬化症患者,比较mPAP 21-24 mmHg组与mPAP≤20 mmHg组,计算敏感性、特异性、PPV、NPV和准确率。
- TAPSE/sPAP在mPAP 21-24 mmHg组低于非PH组(0.58 [0.46-0.72] vs 0.69 [0.57-0.81] mm/mmHg,P<.01)。
- 其他参数在两组间无差异。
- 一氧化碳弥散量<预计值80%识别mPAP 21-24 mmHg的敏感性88.9%、NPV 80%、特异性18.2%、PPV 30.8%。
- TAPSE/sPAP<0.55 mm/mmHg识别mPAP 21-24 mmHg的特异性78.9%、PPV 50%、准确率68.1%、NPV 75.4%、敏感性45.1%。
证据类型、等级与局限
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,TAPSE/sPAP<0.55 mm/mmHg特异性、PPV和准确率最高,可作为附加参数以减少不必要的右心导管。
- 一氧化碳弥散量<预计值80%敏感性最高(88.9%)但特异性低(18.2%),用于识别mPAP 21-24 mmHg时需注意其高假阳性。
指南或共识出处
- 2022年欧洲心脏病学会/欧洲呼吸学会指南
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The 2022 European Society of Cardiology/European Respiratory Society guidelines define pulmonary hypertension (PH) as a resting mean pulmonary artery pressure (mPAP) > 20 mm Hg at right heart catheterization (RHC). Previously, patients with an mPAP between 21 and 24 mm Hg were classified in a "gray zone" of unclear clinical significance.
RESEARCH QUESTION: What is the diagnostic performance of the main parameters used for PH screening in detecting patients with systemic sclerosis (SSc) with an mPAP of 21 to 24 mm Hg at RHC?
STUDY DESIGN AND METHODS: Patients with SSc from the European Scleroderma Trials and Research (EUSTAR) database with available tricuspid annular plane systolic excursion (TAPSE), systolic PAP (sPAP), and mPAP data were included. Patients with mPAP 21 to 24 mm Hg and patients with mPAP ≤ 20 mm Hg were considered for the analysis. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated.
RESULTS: TAPSE/sPAP was lower in the group of patients with SSc with mPAP 21 to 24 mm Hg than in the non-PH group (0.58 [0.46-0.72] vs 0.69 [0.57-0.81] mm/mm Hg, respectively; P < .01). No difference was found in other parameters between the two groups. Diffusing capacity of the lungs for carbon monoxide < 80% of the predicted value had the highest sensitivity (88.9%) and NPV (80%), but the lowest specificity (18.2%) and PPV (30.8%) in detecting patients with SSc with mPAP 21 to 24 mm Hg. TAPSE/sPAP < 0.55 mm/mm Hg had the highest specificity (78.9%), PPV (50%), and accuracy (68.1%); its NPV was 75.4%, and its sensitivity was 45.1%.
INTERPRETATION: In this study, diffusing capacity of the lungs for carbon monoxide < 80% of the predicted value was the parameter with the highest sensitivity and NPV in detecting patients with SSc with mPAP 21 to 24 mm Hg. TAPSE/sPAP < 0.55 mm/mm Hg had the highest specificity, PPV, and accuracy and, therefore, can be a useful additional parameter to decrease the number of unnecessary RHCs.
参考来源
- Colalillo A, Hachulla E, Pellicano C, et al. Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis. Chest. 2024. PMID: 38849072. doi:10.1016/j.chest.2024.05.010
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。